Age ≥50 yearsUnifocal primary breast carcinoma ≤1.5 cmT1N0Hormone receptor+, HER2-Lesion visible on ultrasoundPatient agrees to 5 years minimum adjuvant endocrine treatment. This evidence concerns the gene ERBB2 and breast carcinoma.